A US President for a multi-therapeutic pharma company shouldn't aim to be an expert on every disease. Their primary job is to enable deep subject matter experts, get out of their way, and constantly ask the strategic question: "What's going to take us to that next threshold?"

The industry's costly drug development failures are often attributed to clinical issues. However, the root cause is frequently organizational: siloed teams, misaligned incentives, and hierarchical leadership that stifle the knowledge sharing necessary for success.

Contrary to startup culture, the best training for biotech leadership is gaining broad, cross-functional experience in a large, structured pharmaceutical company. This foundation provides the necessary depth and breadth to navigate the complexities of leading a smaller, resource-constrained biotech later on.

To effectively lead through influence, go beyond aligning on shared business objectives. Understand what personally motivates your cross-functional peers—their career aspirations or personal goals. The most powerful way to gain buy-in is to demonstrate how your initiative helps them achieve their individual ambitions.

Scientists in specialized roles like immunogenicity risk becoming siloed service providers. To maintain impact and growth, they must proactively collaborate with other functions like CMC, safety, and quality. This provides a holistic view of drug development and integrates their expertise into the entire process.

Resvita Bio's team uses a sports analogy for hiring. While an academic lab can thrive with multiple individualistic 'Michael Jordan' superstars, a startup is a team sport. It needs collaborative 'LeBron James' types who elevate the entire team and can play any position to tackle complex, multidisciplinary challenges.

Successful execution of a pharmaceutical launch strategy relies more on soft skills like communication, listening, and team alignment than on purely analytical skills. These behavioral skills are essential for creating cohesive cross-functional teams and ensuring buy-in from those executing the plan.

Developing a new medicine is 'the toughest team sport,' requiring hundreds of people across diverse disciplines over many years. In this context, culture isn't a perk; it's the fundamental 'glue' that enables these disparate teams to work in concert and succeed. Without it, even the best individual players will fail.

The difference between successful and unsuccessful drug hunters isn't intelligence or education, but cultural attributes that exist 'in the margin.' These include radical transparency, honesty, humility, and being part of a supportive, truth-seeking team. These soft skills determine the outcome of high-stakes R&D.